MX2019004402A - Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes. - Google Patents

Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.

Info

Publication number
MX2019004402A
MX2019004402A MX2019004402A MX2019004402A MX2019004402A MX 2019004402 A MX2019004402 A MX 2019004402A MX 2019004402 A MX2019004402 A MX 2019004402A MX 2019004402 A MX2019004402 A MX 2019004402A MX 2019004402 A MX2019004402 A MX 2019004402A
Authority
MX
Mexico
Prior art keywords
methods
inflammatory
treatment
related conditions
metabolic modulators
Prior art date
Application number
MX2019004402A
Other languages
English (en)
Inventor
Batthyány Carlos
López Gloria
Escande Carlos
Rodriguez Duarte Jorge
Porcal Quinta Williams
Dapueto Capuccio Rosina
GALLIUSSI LÓPEZ Germán
GARAT NUÑES María
Hill Marcelo
Segovia Mercedes
Original Assignee
Inst Pasteur De Montevideo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Pasteur De Montevideo filed Critical Inst Pasteur De Montevideo
Publication of MX2019004402A publication Critical patent/MX2019004402A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revelan métodos para tratar condiciones inflamatorias agudas o crónicas, rechazo al trasplante de tejidos, y/o rechazo al trasplante de órganos, dichos métodos comprenden la administración a un paciente que necesita el tratamiento, de una cantidad terapéuticamente eficaz de moduladores antiinflamatorios y metabólicos pluripotentes en combinación con uno o más agente terapéuticos y sus composiciones farmacéuticas.
MX2019004402A 2016-10-14 2017-10-16 Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes. MX2019004402A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408459P 2016-10-14 2016-10-14
US201762570973P 2017-10-11 2017-10-11
PCT/IB2017/056417 WO2018069907A1 (en) 2016-10-14 2017-10-16 Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

Publications (1)

Publication Number Publication Date
MX2019004402A true MX2019004402A (es) 2019-09-26

Family

ID=60382484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004402A MX2019004402A (es) 2016-10-14 2017-10-16 Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.

Country Status (9)

Country Link
US (2) US10537537B2 (es)
EP (2) EP3878456B1 (es)
JP (1) JP6923659B2 (es)
CN (1) CN110325182B (es)
AU (1) AU2017342167B2 (es)
CL (1) CL2019001014A1 (es)
ES (2) ES2945822T3 (es)
MX (1) MX2019004402A (es)
WO (1) WO2018069907A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019004402A (es) * 2016-10-14 2019-09-26 Inst Pasteur De Montevideo Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
US11400066B2 (en) 2016-10-14 2022-08-02 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EP3732162B1 (en) * 2017-12-27 2024-03-06 Institut Pasteur De Montevideo Nitroalkene non steroidal anti-inflammatory drugs (na-nsaids) and methods of treating inflammation related conditions
US10632132B2 (en) * 2018-01-24 2020-04-28 Carlos Batthyány Methods for treating heart transplant rejection
EP3852739A1 (en) * 2018-09-20 2021-07-28 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5113140B2 (es) * 1972-01-13 1976-04-26
WO2005037323A2 (en) * 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Use of gro to treat or prevent inflammation
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
MX2019004402A (es) * 2016-10-14 2019-09-26 Inst Pasteur De Montevideo Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
US10632132B2 (en) * 2018-01-24 2020-04-28 Carlos Batthyány Methods for treating heart transplant rejection

Also Published As

Publication number Publication date
US20220296546A1 (en) 2022-09-22
ES2945822T3 (es) 2023-07-07
US20180104202A1 (en) 2018-04-19
JP6923659B2 (ja) 2021-08-25
AU2017342167B2 (en) 2023-01-12
CL2019001014A1 (es) 2019-11-29
CN110325182A (zh) 2019-10-11
US10537537B2 (en) 2020-01-21
ES2886122T3 (es) 2021-12-16
AU2017342167A1 (en) 2019-06-06
CN110325182B (zh) 2023-05-23
EP3878456A1 (en) 2021-09-15
EP3878456B1 (en) 2023-03-15
JP2019531356A (ja) 2019-10-31
WO2018069907A1 (en) 2018-04-19
EP3525780A1 (en) 2019-08-21
EP3525780B1 (en) 2021-06-02

Similar Documents

Publication Publication Date Title
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
NZ757213A (en) Compositions of plinabulin and use thereof
EA201800199A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
MX370624B (es) Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso.
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
EP3817747A4 (en) TARGETED DELIVERY OF THERAPEUTIC AGENTS TO HUMAN ADIPOCYTES
TW201613578A (en) Pharmaceutical combinations
AR103118A1 (es) Tratamientos médicos basados en anamorelina
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX2018007871A (es) Composiciones para el cuidado personal.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2021005245A (es) Composiciones de oligosacaridos y metodos de uso de las mismas.
EP3908370A4 (en) USE OF PHOTOBIOMODULATION THERAPY TO TREAT INFLAMMATORY AND/OR METABOLIC DISORDERS
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
BR112018014771A2 (pt) composição compreendendo extrato de proteoglicanos de algas e seu uso
PH12014501044B1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells